Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Lexicon Pharmaceuticals Collapsed Today

By Maxx Chatsko - Updated Apr 20, 2019 at 1:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An advisory committee arrived at an impasse on the risk profile of one of the company's drug candidates.

What happened

Shares of Lexicon Pharmaceuticals ( LXRX -2.40% ) fell over 31% today after the company announced that an advisory committee of the U.S. Food and Drug Administration reached a stalemate when deciding whether the benefits of Zynquista outweighed the risks. The final vote was eight in favor of approval and eight against approval. The impasse means investors have no way of knowing the path forward for the drug candidate, although it isn't necessarily doomed. 

That doesn't make the added uncertainty any less painful. Some analysts expected the drug candidate, intended to help treat type 1 diabetes alongside standard insulin treatments, to have blockbuster potential. If it was approved in both type 1 diabetes and type 2 diabetes -- an indication being funded by Sanofi -- then it had the potential to hit peak sales of $1.3 billion by 2024. That might be in doubt now or, at the very least, the timeline has been pushed back. 

As of 10:56 a.m. EST, the stock had settled to a 24% loss.

A disheartened-looking man in a lab coat seated at a table with a microscope and test tubes on it.

Image source: Getty Images.

So what

It's important to note that advisory committee votes do not decide if a drug candidate is granted marketing approval, but rather provide a way for experts to weigh in on the body of clinical trial data. The decision granting marketing approval is ultimately made by regulators at the FDA, who typically follow the recommendation of an advisory committee.

So what happens in a stalemate? A tie goes to the runner, right? Not quite. The split decision injects a healthy dose of uncertainty into the future of Zynquista. The FDA could shake off the concerns of the advisory committee, request additional clinical trials be conducted to collect more data, or outright reject the application from Lexicon Pharmaceuticals requesting marketing approval.

Now what

Few things have the potential to wreck a stock quite like uncertainty. Unfortunately for Lexicon Pharmaceuticals, there's now a fair bit of uncertainty hanging over the regulatory decision for Zynquista. While the surprise advisory committee recommendation doesn't mean the FDA will reject the drug candidate's bid for marketing approval, having to run additional trials would cost millions of dollars and delay its market launch -- if that happens at all. Investors will simply have to wait for the FDA to make its marketing approval decision on March 22.

Check out the latest Lexicon Pharmaceuticals earnings call transcript.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lexicon Pharmaceuticals, Inc. Stock Quote
Lexicon Pharmaceuticals, Inc.
LXRX
$4.47 (-2.40%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
635%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.